
Topic
Medicare Part D
Part D formulary design, IRA negotiated prices, out-of-pocket caps, LIS/Extra Help, and Medicare drug coverage policy.

Pricing & Access· August 1, 2026 · 23 min read

Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D

Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D

Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars

Pricing & Access· July 5, 2026 · 16 min read
Rezdiffra (resmetirom) access: MASH drug coverage and UK MHRA authorization

Policy· June 30, 2026 · 17 min read
IRA Medicare Drug Negotiation Proposed Rule: Market-Access Analysis
By Ran Chen#IRA Negotiation#CMS#Market Access

Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing

Policy· June 21, 2026 · 7 min read
Sitagliptin's May 2026 Generic Launch and Januvia's IRA MFP Termination

Pricing & Access· June 9, 2026 · 10 min read
Awiqli coverage guide: insulin icodec access, PA criteria, and Part D pricing

Policy· June 9, 2026 · 12 min read